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Growth factors ara a diverse subgroup of proteins, but most meet 
the following requirements: (i) they are polypeptides, (ii) initiation 
of response to growth factors occurs outside the cell, (iii) formation 
of a specific Receptor complexed to the growth factor initiates a 
response, (iv) the formation of the growth factor receptor complex 
results in a specific hypertrophic (increase in cell size) response, (v) 
the growth factor and its receptor are removed by receptor-mediated 
endocytosis which leads to degradation of the ligand and perhaps the 
receptor (1). 
Evidence for the requirement of growth factors for growth and 
development can be seen from the fact that cells removed from an 
organism and cultured in vitro require specific proteins and 
polypeptides. Many of these factors have been isolated and purified 
from diverse sources, such as platelets, submaxillary gland, blood 
plasma, pituitary gland, and virally-transformed cells in culture. 
Their functions and interactions are now being studied. 
Two years after the isolation of insulin, researchers found that, 
not only did the peptide regulate carbohydrate metabolism, but it also 
supported cell growth in vitro (2). Hollenberg and Cuatrecasas observed 
that DNA synthesis was initiated upon addition of insulin to human 
foreskin fibroblasts (3). The mitogenic effect of insulin also has been 
shown in liver cells (4) and human diploid cells (5). However, it is 
now believed that insulin acts through the insulin-like growth factor 
receptor to stimulate mitosis. 
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Narva growth factor (NGF) has been purified from mouse 
submaxillary gland (6). Similarities in structure, as well as 
biological effects, suggest that NGF and insulin evolved from a common 
ancestral gene. Levi-Montalcini and Hamburger showed that a diffusible 
factor stimulated the growth of sympathetic ganglia in chick embryos 
(7). That factor was later isolated and named nerve growth factor. The 
mitogenic effects of NGF have been well documented. In chick embryos, 
NGF causes hyperplasia between days 7 and 10 of gestation. For mice, 
NGF only has a mitogenic effect between days 3 and 9 post partum (8). 
Blood platelets were found to be the source of platelet-derived 
growth factor (PDGF), which was later found to be mitogenic for cells of 
mesenchymal origin (9, 10). PDGF also has a role in inflammatory and 
repair processes in vivo. Neutrophils and monocytes were found in close 
proximity to platelets in experimental inflammation models and 
atherosclerosis (11, 12, 13). In addition, platelet extracts were found 
to increase vascular permeability (14, 15). In wound healing, blood 
platelets gather at a wound site and may aid tissue repair by releasing 
platelet-derived growth factor. PGDF is chemotactic for fibroblasts and 
also induces the fibroblasts to proliferate at the wound site (16). 
Another role of PDGF is the activation of human polymorphonuclear leuko­
cytes (17) and monocytes (18). Finally, PDGF increases the release of 
collagenase by fibroblasts (19), a prerequisite for tissue repair (20). 
The cell cycle can be regulated by growth factors in vitro (21, 22, 
23). The cell cycle is composed of four phases in series. The G^ phase 
varies in length of time from as short as 1.5 hours (24) to as long as 
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16 hours ( 2 5 ,  2 6 ) .  Qulascant (non-dlvlding) calls ara ballavad to ba 
"out of oycla" or In Gq. In tha modal davalopad for Balb/c 3T3 calls, 
tha calls raquira stimuli to progress from quiascanca and back into 
cycla. Tha calls must first bacoma "compatant" (22). Two growth 
factors, which hava baan called competence factors, are platelet-derived 
growth factor (POGF) and fibroblast growth factor (PCF) (22, 27). The 
second stimulus is provided by the progression factors, epidermal growth 
factor (EOF) and insulin-like growth factor (IGF). These progression 
factors are said to stimulate the transition of the cells from 
competence to DNA synthesis. 
Epidermal growth factor and basic fibroblast growth factor are two 
more examples of factors that are well characterized. Epidermal growth 
factor and TGF-a seem to be very important to fetal development. EGF 
may contribute to the maturation of fetal lung and aid in prevention of 
hyaline disease (28). Epidermal growth factor also increases the 
synthesis of fibronectin (28) and hyaluronic acid (29, 30), which may 
aid in cell proliferation and development of the basal lamina. Most of 
my work was done with basic fibroblast growth factor, and will be 
discussed in more detail. 
Fibroblast growth factor (FGF) exists in two closely related forms, 
one basic (bFGF) and the other acidic (aFGF). Both forms were first 
partially purified from brain and pituitary by Denis Gospodarowicz ( 3 1 ,  
32, 33). A comparison of the primary structure of the two forms has 
shown that they are closely related with a 5 5 %  sequence identity ( 3 4 ) .  
The basic form of FGF has a pi of 9.6 (35, 36). SDS-polyacrylamide gel 
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•Lactrophorasls ha# rasolvad tha primary translation product for bFGF 
into a band having a molecular weight of 18,000 daltona (36, 37). 
Studies with bFGF have shown that it is a single-chain polypeptide which 
exists in two forms. The first form is composed of 146 amino acids. 
The second form is identical to the first except that the first 15 amino 
acids are missing (38, 39). Both forms of bFGF may be present, 
depending on the organ from which it was isolated. The intact form 
predominates in pituitary, brain, and retina, while the truncated form 
can only be detected in corpus luteum and kidney. The truncated form 
was found to be as potent as the native form. The conclusion has been 
made that the amino-terminus is not involved in binding to the surface 
receptor or in biological activity. 
Higher molecular weight forms of bFGF recently have been reported. 
Moscatelli et al. have described a 25 kOa form (40) while 22, 23, and 24 
kOa forms have been reported by Florkiewicz and Sommer (41) and Prats et 
al. (42). Translation of these larger molecular weight forms of bFGF is 
initiated at a CUG codon rather than the AUG codon (41). 
Basic FGF has both short and long-term effects on responsive cells. 
Vascular endothelial cells become bipolar upon FGF addition (35). At 
6-12 hours, FGF also changes cell morphology. When the mitogen is added 
to confluent/quiescent Balb/c 3T3 cells in culture, the regular 
cobblestone-shaped cells become spindle shaped (43). This effect is 
reversible upon removal of FGF, and the cells return to their normal 
morphology. 
Basic FGF has been implicated in early embryonic development. A 
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fflRNA that encod#* a protein highly homologous to bFGF has been found in 
Xenopus oocytes (44). Kimelman and Kirschner also have found a cONA 
clone that encodes a protein which is 84% homologous to bFGF in the 
neural stage of development in xenopus (45). FGF may play a role in 
limb-bud development. When FGF was injected into denervated early 
regenerates of newt limbs, mitotic activity in the dedifferentiated 
mesodermal cells was increased (46). In myoblast cell lines, bFGF 
inhibits synthesis of actin mRNA (47). bFGF also stimulates the 
proliferation of myoblasts and delays their differentiation by 4-12 days 
in chick myoblasts (48). The inhibitory effect on differentiation has 
been attributed to the ability of FGF to maintain myoblasts in a growing 
state and prevent them from becoming terminally differentiated (49). 
The addition of bFGF can increase the survival (49), as well as 
neurite outgrowth in fetal rat hippocampal neurons (50). In addition to 
being a neurotropic agent in the central nervous system, other neurons 
have been shown to be responsive to FGF stimulation. Addition of bFGF 
increased survival of embryonic chick ciliary ganglia neurons to levels 
observed when ciliary neurotrophic factor was added (51). Basic FGF can 
not only act as a morphogen for nerve cells, but as a mitogen as well 
(52). In fact, bFGF stimulates the growth of a large variety of cells 
in culture. Mouse and human fibroblasts (53, 54), chondrocytes (55), 
and endothelial cells (56) all are stimulated by FGF. This mitogenic 
activity on a variety of cell types may play a crucial role in the wound 
healing process. It is hypothesized that bFGF is released from 
macrophages (57) and stimulates the proliferation of capillary 
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endothelial celle (58) and vascular smooth muscle (59). In addition to 
being mitogenio, F6F also stimulates carbohydrate, nucleotide, and amino 
acid transport, as well as promoting mRNA and protein synthesis (56, 60, 
61). 
There is another group of proteins, called the interferons, which 
are important in intercellular communication. There appear to be three 
major classes of interferons (62, 63): leukocyte or alpha interferon 
(IFN-a)f fibroblast or beta interferon (IFN-fi); and immune or gamma 
interferon (IFN-&). The first group of interferon, IFN-a, was first 
purified in the late 1970s (64, 65). Namalva cells (66), peripheral 
blood leukocytes from patients with leukemia (67), and KG-1 cells (68) 
have been sources for isolating and purifying iFN-a. There are a number 
of different species of IFN-a from each of these sources. The molecular 
weights of these IFN's range from 16 kOa to 27 kDa (69, 70, 71). The 
isoelectric points of these proteins are diverse, ranging from 5.5 to 
6.5 (72), but the proteins have approximately 70% sequence identity (62, 
67, 68, 73). Some of the alpha interferon species are glycosylated, 
while others are not (74). 
Human IFN-Û was the first interferon to be purified (75). Only 
one species, having a molecular weight of 20,000 daltons, was purified. 
Two forms of mouse IFN-J3 have been isolated. Class A IFN-Q has a 
molecular weight of 35,000 daltons and class B has a molecular weight of 
26,000 daltons (76, 77). 
Three forms of IFN-# have been reported, having apparent molecular 
weights of 15,500-17,000 daltons, 20,000 daltons, and 25,000 daltons 
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(78, 79, 80). Tha difference# in apparent molecular weight* eeemingly 
im caused by the amount of glycosylation (80). 
The interferons exhibit a large number of biological effects, but 
primarily two effects have been studies in great detail. When IFN-y was 
purified, it was found that fractions containing interferon had 
antiproliferative activity (81). In earlier studies, it also was 
discovered that interferon had antiviral activity (82). This type of 
activity is related to the two interferon-inducible, double-stranded 
RNA-dependent enzymes, (2'-5')-oligoadenylate (2,5-A^] synthetase (83) 
and Pl/eIF-2 protein kinase (84). Both the synthetase and kinase must 
be activated by double-stranded RNA following induction by IFN (85, 86). 
There are three enzymes in the (2'-5')-oligoadenylate synthetase system: 
the 2'-S' synthetase, an endoribonuclease, and a phosphodiesterase (82, 
87, 88). The (2'-5')-oligoadenylate synthetase is induced to varying 
levels by IFN, depending upon the type and growth state of the cells. 
The 2,5-Ap-dependent endoribonuclease catalyzes the cleavage of viral 
and cellular RNA on the 3' side of -UpXp- sequences (89). The (2'-5') 
phosphodiesterase converts the (2'-5')-oligoadenylate synthetase 
products into AMP and ATP (90). The Pl/eIF-2 protein kinase 
phosphorylates the PI protein, which is a ribosome-associated protein 
(89), and the translation initiation factor, eXF-2 (91). A hypothesis 
of how these proteins are involved in the antiviral activity of 
interferon is that interferon induces synthesis of the kinase and the 
synthetase. Double-stranded RNA activates both enzymes, which leads to 
phosphorylation of eIF-2 , and repression of initiation of mRNA 
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translation. Activation of th# oligoadenylat* synthetaa* converts ATP 
to 2'-5'-oligoadenylic compounds, which activate the endo-ribonuclease 
enzyme to degrade messenger and ribosomal RNAs. The induction of the 
phosphodiesterase turns the system off by converting the oligoadenylate 
synthetase products into AMP (92). 
Several experiments have shown that interferon acts through cell 
surface receptors (93, 94). IFN-a and INF-A share a common receptor 
(95, 96), whereas IFN-X has its own specific receptor (97). The 
mechanism by which the receptor signals has not been elucidated. 
However, studies with mutants of a macrophage cell line, which are 
defective in the cAMP second messenger system, have shown that the 
antigrowth activity, but not the antiviral activity, may be through a 
cAHP-dependent mechanism (98, 99). 
Human IPN-a/8 stimulates a rapid increase in diacylglycerol and 
inositol tris-phosphate levels (100, 101). Addition of IFN-a produced a 
rapid alkalinization and influx of Na*, presumably by a Na*/H* 
antiporter (102). The postulated mechanisms of ZFN and growth factor 
signaling may be very similar. In support of this hypothesis, one study 
has found that IFN-f levels can be regulated by the growth factors PDGF, 
EOF, and FGF in mouse spleen cells (103). 
Croton oil from the Croton tialium plant was fractionated by 
Hecker (104) to isolate the constituent responsible for enhancing tumor 
formation in animals treated with a carcinogen. The compounds were 
found to be derivatives of the tetracyclic diterpene phorbol. The most 
potent tumor promoter was 12-0-tetradecanoylphorbol-13-acetate (TPA). 
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An alteration in cell morphology ia the roost noticeable effect of the 
phorbol ester. Addition of the tumor promoter caused the cells to 
become less flattened, more refractile, and increased extension of the 
cellular processes (105, 106, 107) in Balb/c 3T3 cells. As well as 
altering the morphology of the cells, TPA also mimics the effect of 
growth factors by stimulating cell division (108) and DNA synthesis 
(109), increasing the number of microtubules (110), inducing the 
production of ornithine decarboxylase (111, 112, 113) and collagenase 
(114, 115, 116). 
Turnover of phosphatidylinositol and subsequent signal transduction 
have been studied for many years (117). It is now known that activation 
of a phospholipase C results in turnover of inositol phospholipids 
(118). This type of cleavage results in the rapid appearance of 
inositol 1, 4, S-trisphosphate (116) and diacylglycerol (119, 120, 121). 
Addition of inositol l,4,5-trispho8phate to hepatocytea and pancreatic 
+2 
acinar cells induced the release of Ca into the cytoplasm, which was 
taken up by nonmitochondrial stores (122, 123). Prentki et al. have 
found that inositol 1,4,5-trisphophate causes a rapid release of Ca*^ 
from microsomal fractions of rat insulinomas (124). Diacylglycerol is 
normally absent from membranes and its formation initiates the 
activation of protein kinase C (125). In human platelets, 40 and 20 kDa 
proteins become rapidly phosphorylated following treatment with agents 
known to cause phosphatidylinositol turnover (121, 126, 127). Various 
synthetic diacylglycerols, such as l-oleoyl-2-acetylglycerol, are very 
effective at activating protein kinase C (128, 129). 
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Minutas after bFGF was added to quiescent Swiss 3T3 cells in 
culture, diacylglycerol was rapidly induced, protein kinase C was 
activated, and Ca*^ mobilized (130, 131). These events correlate with 
c-mvc gene activation (132). Protein kinase C has been implicated in 
tumor promotion (133). Ca*^ has been implicated in cell growth (134, 
135) and c-mvc is an oncogene which transforms a wide variety of cell 
types, including fibroblast, epithelial, and myeloid cells both in vivo 
and in vitro (136, 137, 138) However, some laboratories have found that 
the mitogenic signaling pathway for FGF is not through phosphoinositide 
hydrolysis and protein kinase C activation. Moenner et al. have found 
that addition of the mitogen, acidic or basic FGF, to bovine epithelial 
lens (BEL) cells caused a rapid increase in cytoplasmic Ca*, followed by 
an increase in the intracellular pH (139). They did not find any 
significant breakdown in polyphosphoinositides, however. Magnaldo et 
al. have also found that addition of acidic or basic FGF reinitiated DNA 
synthesis in Chinese hamster lung fibroblsts (CCL39) and they failed to 
detect increased breakdown of phosphoinositides (140). Thus, it seems 
that initiation of DNA synthesis can be regulated by mechanisms other 
than the products of inositol lipid degradation. 
+2 The two pathways of protein kinase activation and Ca release 
appear to be intimately related. A small amount of diacylglycerol 
dramatically increases the affinity of protein kinase C for Ca*^ (141). 
When platelets were stimulated by the synthetic diacylglycerol, 
l-oleoyl-2-acetylglycerol, the 40 kOa protein, previously mentioned, was 
phosphorylated. If a Ca*^ ionophore was added, a 20 kDa protein was 
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phosphorylatad. This indicates the necessity for calcium mobilization 
for this phosphorylation to occur. If the cells were incubated with 
both diacylglycerol and ionophore the resulting phosphorylations of both 
proteins was dramatically enhanced (129, 142). This synergistic 
response also has been observed in other systems, such as release of 
lysosomal enzymes from neutrophils (143), insulin secretion from rat 
pancreatic islets (144), and amylase secretion from pancreatic acinor 
cells (145). 
Protein kinase C is directly activated by 12-0-tetradecanoyl-
phorbol-13-aoetate (146, 147, 148). The structure of the phorbol ester 
is such that it is able to substitute for diacylglycerol both in vivo 
and in vitro (146, 149). As was previously stated, the actions of tumor 
promoters mimic that of growth factors. The hypothesis for this 
similarity is that both act through a common intermediate, protein 
kinase C (131, 146, 148, 150). 
Dexamethasone is a steroid-hormone analog and has been used in many 
studies to investigate the mechanisms and DNA-binding sites for 
glucocorticoids. This class of hormone is essential for tissue 
differentiation during development, control intermediate metabolism, and 
adjust physiological processes in response to stress (151). In the 
target cells, there are about 25,000 intracellular receptor sites which 
are oligomeric phosphoproteins. In one proposed model, the hormone 
enters the cytoplasm and binds to the specific receptor. The complex 
migrates to the nucleus and effects transcription (152, 153). However, 
this two-step model has been challenged. Other laboratories have found 
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that tb# unllgandad glucocorticoid receptor reeide# in the nucleus and 
can bind to DMA hormone reeponaive element# (HRB) (154, 155). 
Phyeiochemical studiee in vitro have shown that steroids can directly 
interact with DMA (156, 157, 158). Studies in vivo have revealed that 
the presence of hormone is required for steroid receptor-HRE to interact 
with DNA (159, 160). The consensus sequence d(TGTTCT)2 found in the 5'-
and 3'-flanking ends of glucocorticoid responsive elements has proved to 
be an enhancer (160, 161). 
Glucocorticoid receptor activity can be activated by dibutyryl-cAMP 
in cultured human skin fibroblasts (162). The cAMP-mediated pathway was 
further implicated in regulating glucocorticoid receptor function by 
Gruol et al., who showed that a murine lymphoma cell line was found to 
have a cytolytic response to both cAMP and glucocorticoids (163). A 
cAMP-dependent, protein kinaae-defective daughter cell line was steroid 
resistant. In addition, cAMP was found to increase levels of steroid 
binding to DNA in the maternal cell line. The interaction of the 
hormone with the nuclear receptor stimulates mRNA synthesis for 
somatotropin (164) and metallothionein (165). Hhereaa glucocorticoids 
stabilize a^-foetoprotein mRNA, despite decreasing its rate of 
transcription (166). The mechanisms by which the receptor-steroid 
complex stimulates or inhibits transcription are unknown. 
Synthesis of secreted proteins occurs when mRNA binds to ribosomes 
and then attach to the endoplasmic reticulum (ER). The rate of 
synthesis is thought to primarily occur through controlling the amount 
of mRNA available for translation. The elucidation of the mechanism of 
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regulation of mRNA turnover has been analysed in three componentst (i) 
the cellular and extracellular signals that trigger the degradative 
mechanism, (ii) the structural elements of the individual mRNAs 
recognized by a degradative component, (iii) modulation of RNA-specific 
nucleolytic enzymes. 
Oestrogens dramatically increase the half-life of vitellogenin mRNA 
(167). Also, type I procollagen message was significantly increased in 
response to glucocorticoids and growth factors (168, 169). The exact 
mechanism is not known, but it is conceivable that proteins, such as 
exo- or endonucleases, may be regulated by inducers, such as growth 
factors or glucocorticoids. Investigators have also found that removal 
of the 5' terminal cap from reovirus mRNA increased the rate of message 
degradation (170, 171). In other studies, the 3' terminal region was 
found to either increase (172, 173) or decrease (174, 175) the mRNA 
turnover. Finally, it has been suggested, that inhibition of protein 
synthesis could lead to the production of some molecules that can act as 
inducers of gene expression. Ringold et al. have proposed that the 
increase in the transcriptional rate of the IFN-fi gene, upon inhibition 
of protein synthesis with cyclohexamide, may be attributed to a labile 
protein which rapidly turns over (176). Elder et al. have found a 5' 
sequence of the B-actin gene, which confers cycloheximide-dependent 
regulation (177). They have suggested that the Q-actin promoter is 
regulated by a labile negative control factor, whose synthesis is serum 
dependent. 
As stated previously, cycloheximide is an inhibitor of the 
14 
elongation procavs of protein eyntheeis in eukaryotic •yateme. It 
revereibly inhibit# the peptidyl transferase enzyme required for 
translocation of the peptide in the ribosome (178). Cycloheximide has 
been shown to induce the synthesis and/or the stabilization of several 
mRNA species (176, 179, 180, 181, 182, 183, 184, 185). Also, the 
products of two oncogenes, c-mvc and c-fgg, can be induced by growth 
factors in the presence of cycloheximide (186). So, too, are the levels 
increased in a set of five secreted proteins in response to stimulation 
by growth factors and cycloheximide (187). These proteins have 
molecular weights (estimated by SDS-polyacrylamide gel electrophoresis) 
of 12,500 (SIP 12), 24,000 (SIP 24), 29,000 (SIP 29), 48,000 (SIP 48), 
and 62,000 daltons (SIP 62). These proteins have been termed the 
"superinducible proteins" (SIPs). The term superinduction was first 
used by Thompson et al. (188) in referring to the additional increase in 
tyrosine aminotransferase activity upon treatment of rat hepatoma cells 
with actinomycin D. 
The superinducible proteins are induced by mitogens in Balb/c 3T3 
fibroblasts. The five SIPs reach their maximum levels within six to 
eight hours after adding E6F, F6F, or serum. Actinomycin D inhibits 
this effect, which suggests that the mitogenic factors regulate 
transcription (189). In metabolic labeling experiments with 3T3 cells, 
when cycloheximide was added during the pre-incubation period before 
protein labeling with ^^S-methionine, production of the SIPs was two to 
five times greater than the addition of growth factor alone. In 
experiments conducted shortly thereafter, it was found that the affect 
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of cycloheximid# wa# •pacific for the SIP# and could not b# a##ociatad 
with an overall increase in protein syntheei#. The exact mechanism for 
the SIP# auperinduction ha# yet to be elucidated. 
Experiment# were performed where polyrl-polyrC, an inducer of the 
interferon#, wa# te#ted for it# ability to induce the level# of the 
SIP#. Two of the SIP#, SIP 12 and SIP 62, were etrongly induced by 
polylC, wherea# the other three were not (189). The exact relationehip 
between the interferon# and the SIP# wa# not known at thi# time, but 
immunoprecipitation experiment# revealed that anti-A-interferon antibody 
did not recognize any of the #uperindueible protein#. 
One hypothe#i# i# that the SIP# are a group of intercellular 
communicator# acting in either an autocrine or a paracrine fashion. I 
inveetigated this hypothesis by purifying SIP 24 from conditioned 
medium, raising antibodies, and developing a radioimmunoassay for SIP 
24. With this technology, the functional aspects of SIP 24 in vivo can 
be investigated. Finally, the effects of bFGF, TPA, and dexamethasone 
and their mechanisms of action on the production of SIP 24 by Balb/c 3T3 
cell# were investigated. 
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PARI I. PURIFICATION AND SEQUENCING OF SIP 24, A 




Basic fibroblast growth factor (bFGF), serum, or epidermal 
growth factor (EOF) Increase the secreted levels of five proteins 
produced by confluent, quiescent Balb/c 3T3 cells (187, 189). The 
levels of these proteins are further increased if the cells are pre-
incubated with the inhibitor of protein synthesis, cyclohexlmide. The 
proteins have molecular weights (estimated by SDS-polyacrylamlde gel 
electrophoresis) of 12,500 (SIP 12), 24,000 (SIP 24), 29,000 (SIP 29), 
48,000 (SIP 48), and 62,000 daltons (SIP 62). This group was called the 
"superinducible proteins" (SIPs), a term which refers to the additional 
increase in protein synthesis by cells, following treatment with an 
inhibitor of macromolecular synthesis (188). In this paper we report 
the purification and characterization of SIP 24. A partial amino acid 
sequence has been obtained, and two peptides were found to have a high 
degree of homology with cyclophilin, a cyclosporin A binding protein 
(190). 
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MATERIALS AND METHODS 
Pwrificatign SH SIR 21 lax. AntibOdY Production 
Balb/c 3T3 mou#* fibroblaat calls warm plated on roller bottles 
(750 cmf. Corning) in Dulbeceo-Vogt's modified Eagles (DME) medium with 
10% calf serum (Gibco) and 10 Units/ml penicillin-streptomycin (Gibco). 
After the cells were confluent, medium was changed to DME containing 2% 
calf serum. Three days later, Ifjg/al cycloheximide (CHX) and 10 ng/ml 
12-0-tetradecanoylphorbol-13-acetate (PMA) were added to the medium and 
the cells were incubated for 14 hours. The cells were rinsed twice with 
Tris-buffered salts, fresh DME containing 10 ng/ml PMA was added, and 
the cells were incubated for 8 additional hours. This process was 
repeated three times with a three-day incubation in DME-2% calf serum 
between eatih treatment. After its collection, 16 liters of SZP-
containing conditioned medium was centrifuged (30 minutes at 12,100 x 
g). A pressure dialysis Amicon unit equipped with a ÏM10 membrane was 
used to concentrate the conditioned medium by 20-fold. The medium was 
placed on a Sephadex G-150 (Pharmacia) column pre-equilibrated with 50 
mM ammonium bicarbonate buffer, pH 8.1. Fractions were collected and 
aliquots analyzed by silver staining of SDS-PAGE gels and 
radioimmunoassay to identify the fractions that contained SIP 24. Those 
fractions containing SIP 24 were pooled and again concentrated using the 
YMIO membrane. 
SIP 24 was further purified by using the electroelution method of 
Hunkapiller et al. (191). The concentrated sample from the G-150 column 
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containing SIP 24 waa combined with sample buffer and resolved by 
preparative 7.5-15% SOS-polyacrylamide gradient gels. The gels were 
stained with Coomassie blue dye for 20 minutes and destained in a 5 mM 
Tris buffer, pH 8. The SIP 24 band could be visualized quite easily and 
was cut from the gel using a razor blade. The gel slice was diced into 
2 mm squares and placed in the elution cells. Elution cells are hollow 
H-shaped pieces which have their lower ends sealed with dialysis 
membrane, having a molecular weight cutoff of 6,000-8,000 daltons. The 
cells were placed in the elution apparatus and electrophoresed for 36 
hours. The Coomassie blue stained protein was transferred from the 
sample collection well to Eppendorf tubes. The methanol/chloroform 
protein precipitation method of Wessel and Flugge (192) was used to 
extract the SOS and staining dye from the protein. The precipitate was 
resuspended in Tris-buffered salts. 
Amino Acid Sequencing 
In later experiments, we found that SIP 24 could be purified more 
readily and with higher yield if reverse-phase HPLC was used in place of 
the electroelution method. The Sephadex G150 (Pharmacia) column 
concentrate was loaded onto a 300 angstrom pore size, Cq reverse-phase 
HPLC column (Phenomenex). A gradient of 0 - 54% acetonitrile/0.1% TFA 
in 40 minutes was used to separate SIP 24 from contaminating proteins. 
Fractions containing SIP 24 were pooled and lyophilized. The protein 
was solubilized in 30mM ammonium bicarbonate, 5mM dithiothrietol, 2mM 
calcium chloride, and 6M urea. Cloatripain (Sigma Chemical Company) was 
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addad at a molar ratio of SO parts SIP 24 to 1 part cloatripain, to giva 
a final concentration of 40 pH cloatripain. The reaction waa allowed to 
go 16 houra at 37°C and then atopped by adding 0.2 ml of 70% formic 
acid. Thia waa freeze dried and lyophilized immediately (193, 194). 
The pellet waa aplubilized in 0.2 ml diatilled water/0.1% TFA and loaded 
onto a C^g reverae-phaae HPLC column (Vydac). Peptidea were aeparated 
on a 0 - 72% acetonitrile/ 0.1% TFA gradient in 150 minutea. Abaorbance 
at 214 run waa monitored and fractiona where peaka were detected were 
frozen and lyophilized. Sequencing analyaia waa performed by blotting 
onto Immobilon P trpnafer membranea (Millipore) and aequencing with an 
Applied Bioayatema 470A protein aequencer equipped with an on-line 120A 
PTH analyzer. The aequencea of the derived peptidea were compared by 
uaing the Protein Identification Reaource (PIR)# Beltaville, Maryland. 
Radioiodination 
SIP 24 waa radioiodinated uaing immobilized lactoperoxidaae and 
glucoae oxidaae (Enzymobead, Bio-Rad). Approximately 5 fjg of SIP 24 was 
placed in a reaction veaael with 1 mCi ^^^I-Na (Ameraham), 0.2% D-
glucoae, and 140 mM phosphate buffer, pH 7.2. After 25 minutea the 
reaction waa atopped by centrifugation (13,600 x g). The aupernatant 
waa placed on a deaalting column (Econo-Pak 10, Bio-Rad) and fractions 
collected. Aliquota of the fractions were analyzed and fractiona 
containing radioactivity were pooled. Acid-insoluble material was 
determined by trichloroacetic acid precipitation. 
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Antibody Production 
Antibodias for SIP 24 war* raiaad by injaeting an amulaion of 20 f jg 
of tha alactroalutad SIP 24 in Fraund'a complata adjuvant intradarmally 
into a famala Naw Zaaland Whita rabbit. Fiva waaka later, another 
injection of 30 fjg protein emulaifiad in Fraund'a incomplete adjuvant 
waa given intradarmally. The rabbit warn bled every aeven daya, 
beginning ten daya after the aecond injection. 
Radioimmunoasaav 
. Media aamplea or known amounta of SIP 24 were diluted in lOmM 
EDTAr 150 mM Bodium chloride, 10 mM aodium phoaphate, pH 7.5 and 1% 
cryatallina bovine aerum albumin. The aamplea were incubated with anti-
SIP 24 immune aerum diluted It1000 for 6 hours at 4*C. To the mixture, 
10,000 cpm of acid-precipitable siP 24 was added. This was 
incubated for 12 hours at 4°C, afterwhich 1% (w/v) Staohvlococcus aureus 
was added and incubated for 1 hour at 4*C. The samples wer* spun in a 
microfuge for 5 minutes, supernatants were removed and the pellets 
counted in a gamma scintillation counter. 
Immyngprfcipitation 
The immunoprecipitation procedure of Fienup et al. (195) was 
followed, except the final dilution of SIP 24 antiaerum was 1000-fold. 
Mstaboiic tabflinq 
Methods for experiments requiring metabolic labeling were those 
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pravioualy described (187). Briefly, Bmlb/c 3T3 cells were plated in 24 
well plastic dishes in OME medium containing 10% calf serum. As the 
cells became 80% confluent, the medium was changed to DME containing 2% 
calf serum. The cells were allowed to become confluent and qpiiescent. 
Additions were made directly to the conditioned medium. After eight 
hours, the medium was removed and the cells were washed twice with Tris-
buffered salts. Labeling was done by adding DME medium (0.1 methionine) 
containing 20 /uM [^^S]-methionine (100-200 pCi/ml; 1 Ci" 3.7 x 10^° Bq), 
0.2% calf serum, and additions that had been added to the medium 8 hours 
earlier. The medium was removed four hours later, and centrifuged at 
3000 X g for 20 minutes. 
Samples were diluted in half with 2X electrophoresis sample buffer 
to give a final concentration of 2% (w/v) sodium dodecyl sulfate; 2% 
(v/v) 2-mercaptoethanol; 10% glycerol; 0.002% bromophenol blue; and 59 
mM Tris PO^ (pH 6.9). The samples were analyzed by SDS-PAGE on 7.5-15% 
polyacrylamide gels. 
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RESULTS AND DISCUSSION 
Pyrififâtlgn 
Confluant, quiaacant Balb/c 3T3 calla wara pralneubatad with 
cyclohaximlda and PMA for 14 houra, waahad/ and than incubatad with PMA 
alona for anothar 8 houra. It waa datarminad that thaaa conditional gava 
tha graataat production of SIP 24 (data not ahown). Tha concentration 
of SIP 24 in the conditioned culture medium uaed for SIP 24 purification 
waa 27 ng/ml, aa determined by radioimmunoaaaay (Table 1). The final 
fold-purification of SIP 24 waa 142.8. It muat be remembered that SIP 
24 ia a aecreted protein, and the aacreted proteina only amount to a few 
percent of total protein ayntheaia. Thua, aeparating aecreted proteina 
from the remaining cellular material providea a 30- to 50-fold 
purification. The medium waa concentrated and reaolved by gel 
Table 1. Purification atepa and yielda of SIP 24. The conditioned 
medium contained 93 g of protein, of which a large portion was 
bovine eerum albumin. The final yield of SIP 24 waa 9.5% of 
















medium IB mm 15,500 420 93 g mm 9m 
G-150 
Fractiona 10.4 350 99 94.5 mg 23.6 
HPLC 142.8 1 40* — 9.5 
*Batimated by densitometry of standards on SDS-PAGE. 
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filtration. Figura 1 shows th# alution profils of SIP 24 and two 
protein standards, crystalline bovine serum albumin, with a molecular 
weight of 65,000 daltons, and carbonic anhydrase, with a molecular 
weight of 30,000 daltons. It can be noted that SIP 24, with an apparent 
molecular weight of 24,000 daltons estimated by SDS-PAGB, elutes with a 
much lower apparent molecular weight from the G-ISO Sephadex column than 
expected on the basis of its electrophoretic mobility. The reason for 
this result is not known, but it greatly increased the ease of 
purification of the protein. After gel filtration, the protein could be 
purified by reverse-phase HPLC. Figure 2 shows the purification of 
proteins from the GlSO/anmonium bicarbonate pooled fractions using 
reverse-phase HPLC. Absorbance was monitored at 280 run and peaks were 
collected. Aliquots of the fractions were lyophilized and analyzed by 
radioimmunoassay. The peak with the retention time of 26 minutes was 
found to be SIP 24. 
Antibody Validation 
Polyclonal antibodies were obtained by injecting electroeluted 
protein into rabbits. The results in Figure 3 show that the antibodies 
thus obtained immunoprecipitate SIP 24. More SIP 24 was 
immunoprecipitated from the medium from cells which had been 
superinduced with cycloheximide and bFGF than from medium from control 
cells. However, only about 10-15% of the labeled SIP 24 protein was 
immunoprecipitated by SIP 24 antiserum in each case. This is a constant 
finding and may be due to the fact that protein used to obtain the 
Figure 1. Elution of SIP 24 (open circles), as well as the tvro protein standards, BSA (-+-) and 
carbonic anhydrase (closed circles), on a G-150 Sephadex/SOmM ammonium bicarbonate pH 
8.1 column is illustrated. SIP 24 was detected using a radioimmunoassay and is 
expressed in fig/ml. The protein standards %fere detected spectrophotometrically with 
absorbance at 280 nm 
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Figure 2. HPLC separation of pooled fractions from the 6150/50 mM ammonium bicarbonate column. 
The concentrated, pooled fractions viere injected onto a 300 angstrom pore size, Cg 
reverse-phase column (4.6 x 250 mm). The sample was chromatographed at a flow rate 
of 1 ml/min. using a linear gradient of 0-54% acetonitrile/0.1% TEA in 40 minutes. 





















Elution Time (minutes) 
Figura 3. Th# ability of antibodies to SIP 24 to Inununopreclpltate the 
protein set. (-) control conditions; (F) 0.5 ng/ml bFGF; (C) 
1 /jl/ml CHX; and (C/F) CHX/F6F; denote the additions made to 
the cells 8 hours before labeling. LM, labeled medium 
samples; IP, Immunopreclpitated samples. The arrow at right 
Indicates SIP 24. The dots at left represent the molecular 
weight markers; cytochrome c (12 kOa), myoglobin (18 kOa), 
carbonic anhydrase (30 kDa), ovalbumin (45 kOa), bovine serum 
albumin (65 kDa), and beta-galactosidase (116 kDa) 
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LM IP 
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31 
antibody for SIP 24 warn electromluted and aubsaquantly denatured. No 
other protein* in the labeling medium were inmunoprecipitated by the 
antiaeruffl. 
Once the antiaerum'a specificity was validated, a radioimmunoassay 
for SIP 24 was developed (Figure 4). To further test the standard 
curve, samples of medium were serially diluted and it was found that the 
dilution curve closely paralleled the standard curve. The 
radioimmunoassay was used to screen column fractions for subsequent 
purification of SIP 24. 
fil£ 21 Characterization 
To determine whether SIP 24 contained N-linked olig6saccharide(*), 
media from metabolically labeled cells after superinduction with and 
without tunicamycin were immunoprecipitated with SIP 24 antiserum 
(Figure 5). A shift in molecular weight from 24,000 daltons to 20,000 
daltons can be seen after treatment with tunicamycin. Both bands at 20 
and 24K were immunoprecipitated by anti-SIP 24 antiserum, but at 
different efficiencies. Only 15% of the 24 kilodalton band compared 
with 50% of the 20 kilodalton band was immunoprecipitated. 
Labeling medium was resolved by electrophoresis on SDS-PA6E under 
reducing and non-reducing conditions. There was a difference in 
mobilities of SIP 24 in SOS-rPAGE from 24 to 21 kilodaltons in reducing 
versus non-reducing conditions (Figure 6). The difference in mobility 
may be due to the fact that addition of 2-mercaptoethanol reduces the 
sulfhydryl groups and breaks the intra-disulfide linkages, thereby 
Figure 4. The radioimmunoassay curve for SIP 24 is shown (closed circles). The validity of the 
assay was tested by serially diluting medium samples (open circles). Note the 
parallelism of the two curves 
RIA STANDARD CURVE 
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Figura 5. The ahift in molecular weight of SIP 24 after incubation 
during the 4 hour radioactive pulse with 1.5 ug/ml 
tunicamycin. All cells were treated with 0.5 ng/ml basic 
fibroblast growth factor for 8 hours before metabolic 
labeling. (-) control; T, 1.5 pg/ml tunicamycin; and C, 1 
ng/ml cycloheximide. LM, the labeled medium samples and 
IP, the immunoprecipitated samples of the labeled medium. 
The smaller arrow at right indicates SIP 24, the larger 
arrow points to the shifted nonglycosylated form. Note 
that the antibody recognizes both forms of SIP 24. Dots 
at the left indicate the molecular weight markers; 
cytochrome c, myoglobin, carbonic anhydrase, ovalbumin, 




rigure 6. The difference in mobilities of SIP 24 in SDS-PAGB under 
reducing and non-reducing conditions. SIP 24 was resolved 
by SDS Page in the presence and absence of 200 mM J3-
mercaptoethanol. R, with 0-mercaptoethanol, NR, without 
, A-mercaptoethanol. The arrows indicate the shift in 
mobilities from the 24 kOa form (smaller arrow), to 21 kOa 
(larger arrow) in reducing versus non-reducing SDS-PAGB. 
The dots at the left are molecular weight markers: 
cytochrome c, 12,000 daltons; myoglobin, 18,000 daltons; 
carbonic anhydrase, 30,000 daltons; ovalbumin, 45,000 
daltons; bovine serum albumin, 65,000 daltons; 0-






opening up the protein and making it have a different mobility on SDS-
PAGB. The amino acid composition of electroeluted SIP 24 was performed 
and the résulta are shown in Table 2. The value for glycine may be an 
overestimate due to the fact that the electroelution buffer contained 
glycine and may have not been completely removed in the 
chloroform/methanol extraction procedure. From this analysis it can be 
determined that SIP 24 has approximately 180 amino acids and a molecular 
weight of 19,602 daltons. This estimate is very close to the 
nongiycosylated estimated molecular weight of the form of SIP 24 which 
was 20,000. 
Amino acid sequencing of peptides generated from clostripain 
digestion (Figure 7) yielded four sequences (Table 3). The longest 
peptide (peak A), -RALSIGEKGFGYKGSSFH-, has a 95.3% fit with 
cyclophilin, a specific cyclosporin A binding protein from both bovine 
and human (190). The peptide -SDNFR- (peak B), also has homology with 
cyclophilin. There are no other proteins that have as high a sequence 
identity as cyclophilin to these two SIP 24 peptides. The third 
sequence (peak C), -RAGQFTLGN-, has 71.4% identity within a seven amino 
acid overlap with glutamate-5-semialdehyde dehydrogenase from 
Escherichia coli. It also has a 71.4% identity with bovine 
thyroglobulin precursor, hepatitus B virus surface antigen, and several 
human HLA class II histocompatability antigens. The fourth sequence 
(peak D), -TFVPSSR-, has an 83.3% identity with serendipity locus alpha 
protein from Droaoohilia melanooaster as its best fit. However, it also 
has a high sequence identity with yeast PRTl protein and elogation 
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Tabla 2. Th# raaulta of amino acid analysis of SIP 24. Tha total of 
180 amino acid# doa# not ineluda tha amino acid# tryptophan or 
cyataina, which wara altarad during aampla praparation 
Numbar of 
Amino acid pmol-ht raaidua# 
Ala 1386 13 
Arg 1308 12 
Aap/Asn 2278 21 
Olu/Gln 2529 24 
Oly 2023 19 
His 120 1 
Ila 830 8 
Lau 1500 14 
Ly# 840 8 
Mat 79 1 
Pha 1071 10 
Pro 811 8 
Sar 1500 14 
Thr 1394 13 
Tyr 142 1 
val 1360 13 
Total residua# 180 
Figure 7. HPLC separation of peptides from clostripain digestion of SIP 24. Approximately 40 
f ig of SIP 24 was solubilized in 30 mM ammonium bicarbonate, 5 mM dithiothrietal, 2 mM 
calcium chloride, and 6 M urea. Clostripain was added at a ratio of 1:50 (1 part 
clostipain : 50 parts SIP 24). The reaction was allowed to procédé 16 hours at 37°C 
and stopped by addition of 70% formic acid. The mixture was lyophilized and the 
pellet solubilized in 0.1% TFA. About 1 ml was loaded onto a C^g reverse-phase HPLC 
column (Vydac). Peptides were separated by a linear gradient of 0-72% 
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Tabla 3. Th# raaulta of amino acid analysis of four paptidaa ganaratad 
by cloatripain digaation of SIP 24 and homologiaa with bovina 
oyolophilin, £. eoli glutamata-S-aamialdahyda dahydroganaaa 
(GSD), and Droaophila alpha protain. Solid linaa indicata 
axaot amino acid matchaa. Daahad linaa indicata conaarvad 
amino acid aubatitutions 
Protain Paptida Saquanca 
SIP 24 RALSIGBKGF6YK0SSFH 
I I I I I I I I I I I I I I - I I 
Cyclophilin RALSTOBKGPOyKGSCPH 
SIP 24 S - D N F R 
•  " I I I  
Cyclophilin T A B N F R 
SIP 24 RAGQFTLGN 
I I I  I I  
GSD DGGQFGLGA 
SIP 24 TFVPSSR 
I I I  I I I  
Alpha protein T F V R S S R 
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factor 1, Salmonalla tvphimurium lndola-3-glycarol phoaphata aynthaaa, 
and kldnay baan plaatocyanln. Baaad on thaaa raaulta, wa auggaat that 
SIP 24 la a nawly Idantiflad cyclophilln-ralatad protain and tharafora 
may bind cycloaporln A. Cyclophllln la a protain with an apparant 
molaeular walght of 17,737 daltona. It alao haa thraa potantlal altaa 
for N-llnkad glycoaylatlon. 
Cyclophllln haa baan Impllcatad In playing an Important rola In T 
lymphocyta activation. Cycloaporln A la a vary potant Immunoauppraaalva 
agant that blocka aarly avanta In halpar T lymphocyta activation and 
pravanta tha proliferation of affactor T and B calla (196, 197). 
Specifically, cycloaporln A pravanta tha production of Intarlaukln 2, 
Intarlaukln 3 and B call growth factor (198, 199, 200). If SIP 24 binds 
cyclosporin A, then It may be Involved In the coordination of Induction 
of specific genes essential for T lymphocyte activation and 
proliferation. 
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PART II. REGULATION OF SIP 24 BY PROTEIN KINASE C 
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INTRODUCTION 
W# hmv# Shown in Part I that SIP 24 has s#qpx#nc# identity with the 
family of proteins known as the cyclosporin binding proteins. 
Cyclosporin A binding protein, also called cyclophilin, is a cytosolic 
protein which binds cyclosporin A. Cyclosporin A is a very potent 
immunosuppressive agent, which prevents the production of interleukin 2, 
interleukin 3, and B cell growth factor (198, 199, 200). Production of 
interleukin 2, interleukin 3, and B cell growth factor seemingly is 
blocked during helper T lymphocyte activation which subsequently 
prevents proliferation of B and T cells (196, 197). Cyclosporin A has 
been implicated in playing a role in T lymphocyte activation and 
proliferation. 
Early research on SIP 24 induction found that addition of 
fibroblast growth factor (FGF) to Balb/c 3T3 mouse fibroblast cells 
increased expression of SIP 24 (187). Fibroblast growth factor exists 
in two closely related classes, one basic (bFGF), and the other acidic 
(aFGF). Addition of bFGF to cells in culture has a large number of 
effects. Basic fibroblast growth factor acts as a mitogen for a large 
variety of cells in culture (47, 51, 53, 54). It has been implicated in 
embryonic development (55), limb-bud development (56), and neurite 
survival (60). Another dramatic effect of bFGF is the selective 
induction of certain secreted proteins (61, 187). He have found that 
epidermal growth factor (EGF) and serum, as well as bFGF, selectively 
stimulate Balb/c 3T3 cells to synthesize the superinducible protein 
having a molecular weight of 24^000 daltons (SIP 24) (187). 
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Minutas after bFOP was added to quiescent Swiss 3T3 cells in 
culture, diacylglycerol was rapidly induced and protein kinase C was 
activated (131, 132). However, other laboratories have found that the 
signaling pathway for F6F probably is not through phospholnositide 
hydrolysis and protein kinase C activation (139, 140). In Chinese 
hamster lung fibroblasts, bFGF did not Induce the breakdown of 
polypholnos it ides, but still initiated DNA synthesis. 
Rozengurtz has found that addition of bFGF elevates the levels of 
cyclic AMP, thereby implicating the cAMP-dependent protein kinase (201). 
The activating transcription factor consensus sequence for cAMP is 5'-
GTGACGT^g^Q-3'(ORE) (202). The AP-1 DNA binding site, TRE, differs from 
the ORE by only one position. The two transcriptional factors, one 
mediating induction by cyclic AMP, called CREB (203), and the other 
mediating induction through protein kinase C, called AP-1 (204). There 
now appears to be more of a cooperative interaction between the two 
factors. First came evidence that the AP-1 site of the SV40 enhancer 
was not required for TPA induction (205). Then, Duetsch et al. found in 
two cell lines that the ORE only responds to cAMP, however the TRE 
responds to both TPA and cAMP (206). There has been found a region of 
the CREB protein which is similar to AP-1. This region is part of the 
DNA-bindlng domain and includes a leucine zipper motif, which is thought 
to play a role in the dimerlzation of AP-1 (207, 208). So, it is 
possible that CREB and AP-1 may interact to form heterodimers. Thus, 
conferring responsiveness to both cAMP and TPA. 
In this report, we show that the increased levels of expression of SIP 
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24 by th* phorbol eater, 12-0-tetradecanoylphorbol-13-acetate (TPA) and 
the growth factor bFOP, are through the aame aecond meaaenger pathway 
which ia the protein kinaae C mediated pathway. Expérimenta with the 
glucocorticoid analog, dexamethaaone (DEX), and agents which increaae 
the intracellular concentration of cyclic AMP indicate that the cAMP-
dependent protein kinaae ayatem may also regulate SIP 24 expreaaion. 
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MATERIALS AND METHODS 
Basic FOF was obtained as a gift from D. Gospodarowicz (University 
of California, San Francisco). ^^S-methionine (1195-1500 Ci/mmol) was 
purchased from Amersham. The antibody to SIP 24 was made in rabbits 
(manuscript in preparation). Stock cultures of Balb/c 3T3 cells were 
grown in Dulbecco-Vogt's modified Eagle's medium supplemented with calf 
serum and maintained at 37°C in a water-saturated atmosphere with 13% 
COg. 
The amount of ^^S-methionine incorporated into specific proteins 
released into the extracellular medium was measured as described by 
Nilsen-Hamilton et al. (209). Balb/c 3T3 cells were plated on multiwell 
plastic dishes in Dulbecco's-modified Eagles medium with 10% calf serum 
and grown until approximately 90% confluency. The medium was changed to 
fresh Dulbecco's-modified Eagles medium with 2% calf serum for 3 days to 
allow the cells to become quiescent. Basic FGF (0.5 ng/ml), TPA (10 
ng/ml), DEX (400 ng/ml), the diacylglycerol, GAG (10 pg/ml), and 
cycloheximide (1 pg/ml) were added to the conditioned medium for 8 
hours, and the cells labeled with S-methionine in the absence of 
cycloheximide for 4 hours as described previously (209). 
Medium samples containing labeled protein were immunoprecipitated 
with anti-SZP 24 antiserum at a final concentration of 1% antiserum. 
The immunoprecipitation procedure of Fienup et al. (195) was followed. 
The immunoprecipitated samples were resuspended in electrophoresis 
sample buffer, which gave a final concentration of 2% (w/v) sodium 
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dodaeyl aulfata; 2% (v/v) 2-m*tcapto#thanol; 10% glycarol; 0.002% 
bromophanol blua; and 59 mM Tria-PO^ (pH 5.9),and raaolvad by 
alaetrophoraaia on 7.5-15% gradient SDS-polyaerylamide gela. 
Fluorography and acanning with a danaitometer ware uaed to quantitate 
the protein banda. Aacending thin layer chromatography of poatnuclear 
aupernatant aamplea on ailica gel impregnated glaaa fiber atripa with 
30% methanol/10% TCA/10% acetic acid waa uaed to determine the amount of 
incorporated ^^S-methionine in cellular proteina. 
The reaulta from acans ware normalized to the rate of protein 
ayntheaia by dividing the value of each area from denaitometer readinga 
by the total amount of acid-inaoluble, ^^S-methionine radioactivity 
incorporated into the cella of each reapective aample. Two triala of 
each experiment were conducted, and within each trial each treatment was 
duplicated, giving a total of four replicationa per treatment. 
Analyaia of treatment effecta on normalized SIP 24 production were 
evaluated uaing general linear model (GLM) procedurea in SAS (210). 
Subaequently, meana were compared uaing Leaat Significant Difference 




Tha amount of ^^s-mathlonina incorporatad into SIP 24 aacratad by 
Balb/c 3T3 calla waa aynargiatically (graatar than tha aum of tha two 
traatmanta aaparataly) incraaaad by a combination of CHX and DEX (Fig. 
8). To confirm that the protein induced waa SIP 24, an 
immunopracipitation of labeling medium was performed with SIP 24 
antiaarura. When cells are labeled under conditiona of auperinduction 
(CHX/DEX), aignificantly more protein ia immunoprecipitatad than under 
control conditiona. 
Protein Kinagg S Pff^hWftY 
The level of SIP 24 expression also was selectively increased by 
addition of CHX and TPA, and a synergistic increaae was seen in response 
to the combination of CHX and TPA (Fig. 9). To confirm that the protein 
induced by TPA waa SIP 24, an immunopracipitation of labeled medium was 
performed with antiserum to SIP 24. We found that under the conditions 
of induction more protein waa immunoprecipitatad than under control 
conditiona. 
The diacylglycerol, l-oleyl-2-acetyl-glycerol (OAG), cauaed a 
aignificant two-fold increase in SIP 24 levels above control levela 
(Fig. 10). The combination of CHX and OAG caused an almost three-fold 
increaae in SIP 24 levels, but it waa not a synergistic increase. 
For a second series of experiments, SIP 24 expression for control, 
Figure 8. Effects of an 8 hour incubation of 1 /ug/ml CHX, 400 ng/ml 
DEX, and CHX/DEX on SIP 24 production. Following 
incubation, cells were metabolically labeled for 4 hours 
with 20 (jH S-methionine. Bars indicate standard errors. 
LSD • 7.03. n"4 Normalized SIP 24 production refers to 
the value of the densitometric scan of SIP 24 divided by 
the total amount of acid-precipitable, ^^S-methionine 
labeled material in each sample 
NORMALIZED SIP24 PRODUCTION 
o 4^ m K» «y 
Figura 9. Effects of an 8 hour incubation of 1 pg/ml CHX, 10 ng/ml 
TPA, and CHX/TPA on SIP 24 production. Following 
incubation,cells were metabolically labeled for 4 hours 
with 20 fdH S-methionine. Bars indicate standard errors. 
LSD = 2.36. n=4 
NORMALIZED SIP24 PRODUCTION 
€» 9» 40 M 
Figure 10. Effects of an 8 hour incubation of 1 pg/ml CHX, 10 pg/ml 
OAG, and CHX/OAG on SIP 24 production. Following 
incubation, cells were metabolically labeled for 4 hours 
with 20 (iH S-fflethionine. Bars indicate standard errors. 
LSD • 2.83. n*4 
NORMALIZED SiP24 PRODUCTION 
I 
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CHX, and firmt addltivas war# avaluatad in th# praaanc# of a aacond 
additiva. For aaoh of th#a* #xp#rim#nta th# affacta of bPOP, TPA, and 
DEX on SIP 24 axpraaaion wara atudiad with and without th# addition of 
H7 (50 fig/ml), cholara toxin (100 ng/ml), forakolin (50 pg/ml), 
dibutyryl cAMP (10 pM), and th* cAMP-dapandent protain kinaa# inhibitor, 
H-8 (2 pM). Finally, th# affact of th# inactiv# phorbol #at#r, 4-0-
mathyl-TPA varaua tha addition of TPA waa avaluatad. 
Addition of 50 pg/ml of tha protain kinaa# C inhibitor, H-7, did 
not altar SIP production wh#n combined with CHX, DEX, or CHX/DEX (Figa. 
11A,B,C). How#v#r, SIP production in CHX/bFGF, CHX/TPA, and bFGF, TPA 
tr#atffl#nta fall by 34.7% and 46.3%; and 43.6% and 41.3%, rospectivoly, 
in th# pr#a#nc# of H7 (Figa. IIA, B). Wa noted that when 100 pg/ml of 
H-7 waa added to cella, a large number of cells came off the dish. 
Addition of 50 pg/ml H-7 did not cause cells to detach. 
Balb/c 373 cells were preaaturated with 250 ng/ml of TPA or the 
inactive analog phorbol eater, 4-0-methyl-TPA for 48 hours. SIP 24 
levels were higher in cells preincubated with analog compared to TPA 
when the cells were stimulated with bFGF, TPA, CHX/bFGF, and CHX/TPA 
treatments (Figs. 12A, B). Pretreatment with TPA, however, did not 
dacreaae SIP 24 levela in DEX or CHX/DEX treatments (Fig. 12C). In 
fact, a alight increaae in SIP 24 can be aeen in TPA compared with 
analog preincubated cella. This is probably the residual of the SIP 24 
induced by the original addition of TPA in the preincubation. 
Cyclic ME Dependent ProtSin Kin*99 Pathwav 
In the experiments to evaluate the effect of cholera toxin. 
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addition of 100 pg/ml cholera toxin significantly increased SIP 24 
expression (F > 9.55; df • 1, 23; p < 0.005) (Figs. 13A, B, C).. Cholera 
toxin significantly increased SIP 24 levels in control cells and cells 
treated with CHX (Figs. 13A, B, C). Cells treated with bFOF, TPA, DEX, 
or the stimulant in combination with CHX did not show any significant 
increase upon stimulation with cholera toxin. 
When 50 fjg/ml forskolin was added to control and cycloheximide 
stimulated cells, the level of expression of SIP 24 was increased under 
all treatments (Figs. 14A, B, C). However, the presence of bFGF, TPA, 
DEX or bFGF, TPA, or DEX in combination with CHX did not increase SIP 24 
levels in the presence of forskolin (Figs. 14A, B, C). Analysis of 
variance indicated that the effect of forskolin differed significantly 
when cells were treated in the presence of the inducers of SIP 24 
compared with in the absence of inducers of SIP 24 in each of the three 
series of experiments (F>4.39; df » 1, 23; p<0.014). 
The results of the addition of 10 /jH dibutyryl cAMP closely 
parallel that of forskolin (Figs. ISA, B, C). The addition of dibutyryl 
cAMP to control or CHX-stimulated cells caused a significant increase in 
SIP 24 expression. However, SIP 24 did not increase further in cases 
where bFGF, TPA, or DEX were added with cAMP. Butyrate did not increase 
the levels of SIP 24 expression (data not shown). 
Table 4 illustrates the results of experiments with the cAMP-
dependent protein kinase inhibitor, H-8. At a concentration of 2 fjM, H-
8 did not alter SIP 24 expression. 
Figure 11. Effects of an 8 hour Incubation of 1 /jg/ml CHX, an 
additive, and CHX/addltive alone and in combination with 
50 pg/ml H7 on SIP 24 production. Following Incubation, 
cells were metabollcally labeled for 4 hours with 20 pH 
^^S-methlonine. Bars Indicate standard errors. The 
additive for each experiment was: A. 0.5 ng/nl bFGF, LSD 
« 3.42; B. 10 ng/ml TPA, LSD • 2.04; and C. 400 ng/ml DBX, 
LSD " 5.072. n>4 
1 
NORMALIZED 8V>24 PRODUCTION NORMALIZED SiP24 PRODUCTION NORMALIZED SIP24 PRODUCTION 
Figura 12. Effect* of an 8 hour incubation of 1 pg/ml CHX, an 
additive, and CHX/additive in combination with either 250 
ng/ml of 4-0-methyl TPA (analog) or TPA on SIP 24 
production. Following incubation, ce^lle were 
metabolically labeled for 4 houra with 20 /uM ^^S-
methionine. Bar* indicate standard errors. The additive 
for each experiment wast A. 0.5 ng/ml bFOF, LSD • 1.95; 
B. 10 ng/ml TPA, LSD = 1.36; and C. 400 ng/ml DEX, LSD = 
3.36. n"4 
I 
NORMALIZB) SIP24 PRODUCTION NORMALIZED S»>24 PRODUCTION NORMALIZED SIP24 PRODUCTION 
Figura 13. Effacts of an 8 hour incubation of 1 pg/ml CHX, an 
additive, and CHX/additive, alone and in combination with 
100 ng/ml cholera toxin, on SIP 24 production. Following 
incubation, cells were metabolically labeled for 4 hours 
with 20 /iM ^^S-methionine. Bars indicate standard 
errors. The additive for each experiment was: A. 0.5 
ng/ml bFGF, LSD = 4.27; B. 10 ng/ml TPA, LSD - 3.85; and 
C. 400 ng/ml DEX, LSD » 7.26. n=4 
NORMAUZED SIP24 PRODUCTION NORMAUZED SIP24 PRODUCTION NORMALIZED 8IP24 PRODUCTION 
Figure 14. Effects of an 8 hour incubation of 1 pg/ml CHX, additive, 
and CHX/additive alone and in combination with 50 fig/tal 
forakolin on SIP 24 production. Following incubation, 
cells were metabolically labeled for 4 hour# with 20 fuH 
^^S-methionine. Bare indicate standard errors. The 
additive for each experiment was: A. 0.5 ng/ml bFGF, LSD 
= 2.21; B. 10 ng/ml TPA, LSD » 1.94; and C. 400 ng/ml 
DBX, LSD « 4.14. n>4 
I 
NORMALIZED SIP24 PRODUCTION NORMALIZED SIP24 PRODUCTION NORMAUZB) SIP24 PRODUCTION 
Figure 15. Effects of an 8 hour incubation of 1 pg/ml CHX, an 
additive, and CHX/additive alone and in combination with 
10 fiH dibutyryl cAMP on SIP 24 production. Following 
incubation, cells were metabolically labeled for 4 hours 
with 20 fjH ^^S-methionine. Bars indicate standard 
errors. The additive for each experiment was: A. 0.5 
ng/ml bFGF, LSD • 2.09; B. 10 ng/ml TPA, LSD • 2.37; and 
C. 400 ng/ml DEX, LSD « 3.98. n>4 
normalized sip24 production normalized sip24 production normalized sip24 production 
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Tabla 4. Effect of an 8 hour incubation of 1 pg/nl CHX/ 0.5 ng/ml bF6F/ 
10 ng/ml TPA, and 400 ng/ml DBX on normalized SIP 24 
production (+ SB) with and without the addition of 2 pM H-8, a 
cAMP-dependent protein kinase inhibitor. Following 
incubation, cells were metabolically labeled for 4 hours with 
20 liH ^^S-methionine. n«2 
Treatment No H-8 H-8 added 
Control 1.19 ± 0.20 0.82 ± 0.12 
CHX 2.41 + 0.68 2.78 ± 0.94 
bFOF 3.35 ± 0.27 3.91 + 0.19 
CHX/bFGF 7.47 ± 1.27 7.44 + 1.52 
Control 1.44 ± 0.17 1.25 ± 0.16 
CHX 2.81 + 1.00 2.46 ± 0.88 
TPA 3.76 + 0.84 3.70 + 0.73 
CHX/TPA 8.36 ± 1.62 7.55 + 1.45 
Control 0.90 ± 0.23 0.89 ± 0.11 
CHX 1.90 + 0.43 1.92 + 0.41 
DBX 5.17 ± 0.09 5.24 + 0.18 
CHX/DBX 18.94 ± 2.77 18.58 + 2.34 
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DISCUSSION 
In this report, w# showed that the glucocorticoid analog, 
dexamethasone. Increased the secreted levels of SIP 24. He also showed 
that dlbutyryl-cAMP addition caused an Increase In the level of SIP 24 
expression. It Is known that the glucocorticoid receptor can be 
activated by dIbutyryl-cAMP In human skin fibroblast cells (162). The 
cAMP-medlated pathway was further Implicated In glucocorticoid receptor 
function when Oruol et al. showed that a lymphoma cell line had a 
cytolytic response to cAMP and glucocorticoids (163). In that same 
study. Increases In cAMP were found to Increase the binding of steroids 
to DNA. 
Our experiments with the stimulants forskolln and cholera toxin 
add further support to the hypothesis that increasing Intracellular cAMP 
levels increases SIP 24 expression. Both act to increase cAHP levels, 
the former by directly activating adenylate cyclase, the latter by ADP-
rlbosylatlng the a-subunlt of the stimulatory/regulatory subunit of 
adenylate cyclase. 
Our results show that protein kinase C mediates the induction of 
SIP 24 by FGF. We have shown that addition of 
12-0-tetradecanoylphorbol-13-acetate increases SIP 24 expression. To 
further Investigate this phenomenon, the intracellular activator of 
protein kinase C, l-oleyl-2-acetyl-glycerol, was added to cells and 
shown to increase SIP 24 expression. Addition of CHX and OAG together, 
however, did not result in a synergistic increase in SIP 24 expression. 
It is not known at this time why this occurred. One possibility is 
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that, in order to get euperinduotion, activation of protein kinase C 
must be muetained for a longer period of time than diacylglycerol is 
biologically active. As a further test to determine if the protein 
kinase C pathway is involved in SIP 24 expression, the PKC inhibitor, 1-
(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7), was added to 
stimulated cells. H-7 has been found to be the most potent of the 
isoquinoline compounds for inhibiting protein kinase C (212). Under 
conditions of superinduction (CHX/bFGF and CHX/TPA), H-7 decreased the 
level of SIP 24 significantly. Cells treated with CHX/DEX did not show 
this decrease when H-7 was added. 
The results of saturation studies with TPA also lead to the 
conclusion that protein kinase C mediates the FGF effect. Pretreatroent 
with TPA decreased the effect of bFGF and TPA in both the presence and 
absence of CHX. There was no statistically significant decrease in SIP 
24 levels in response to DEX. Thus, it indicates that bFGF, but not 
DEX, acts through protein kinase C to induce SIP 24 levels. 
Results from our experiments with agents which increase 
intracellular cAMP levels show that a cAMP-dependent pathway also can 
regulate SIP 24 expression. Rozengurt has found that addition of bFGF 
to 3T3 cells, under serum-free conditions, resulted in the increase of 
intracellular cAHP levels, indicating that cAMP is involved in mediating 
the FGF signal. Prostaglandins E^ and B2 also increase the level of 
cAMP in 3T3 cells (201). However, prostaglandins E^ and B2 do not 
increase the expression of SIP 24 (data not shown). The concentration 
of dibutyryl cAMP used to increase SIP 24 expression was considerably 
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higher than achieved with the proatagiandina and sustained for a longer 
duration than in the case for the prostaglandins. Therefore, even 
though agents which increase cAMP levels intracellularly may increase 
SIP 24 expression, this is likely to be of pharmacological, rather than 
physiological interest. 
In all conditions tested where agents were added that elevate cAHP 
levels (cholera toxin, forskolin, and dibutyryl cAMP), a synergistic 
interaction can be seen between CHX and the corresponding agent. Also, 
a synergism was detected between CHX and TPA, an activator of protein 
kinase C. This data leads us to believe that cycloheximide may act 
through a mechanism different from the cAMP or protein kinase C 
pathways. 
Experiments conducted in 1985 showed that the transcriptional 
inhibitor, actinomycin D can completely eliminate the increased 
expression of SIP 24 by growth factors and cycloheximide (189). So it 
appears that CHX, bF6F, TPA, and OEX are working at the level of 
transcription. As was discussed before, the AP-1 and CREE binding 
studies indicate that cooperation can occur such that responsiveness to 
both CAMP and TPA is possible. It was found that the AP-1 site is not 
required for TPA induction (205). Also, the cyclic AMP regulatory 
element only responds to the cAMP regulatory element binding protein 
(CREB), but the AP-1 binding site responded to both CREE and AP-1 (206). 
This flexibility in responsiveness to both proteins is thought to occur 
because of a shared protein motif, called the leucine zipper, which 
would allow the two binding proteins to interact and form heterodimers 
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(207, 208). P«rhapa this is what i# occurring in our particular cas*. 
Elder *t al. have found that the 5' ••quanca of tha B-actin promoter ia 
ragulatad by a labile negative control factor (171). A aimilar model 
could be propoaed for auparinduction of SIP 24. 
The next queation waa whether DBX, cyclic AMP, and the protein 
kinaae C mediated pathwaya are required together in order to increaae 
SIP 24 expreaaion. When protein kinaae C ia inhibited by H-7 or 
depleted by prior treatment with TPA, DEX can atill increaae levela of 
SIP 24. The glucocorticoida do not need PKC to mediate induction of SIP 
24, although FOF aeemingly doea. 
From the evidence preaented, we hypotheaize that the pathway for 
regulation of SIP 24 expreaaion by PCF ia through protein kinaae C. 
However, dexamethaaone doea not appear to be regulating through the 
protein kinaae C mediated pathway. He have also preaented evidence 
which ahowa that cAMP and the cAMP-mediated pathway can regulate SIP 24 
expreaaion, but it ia not clear whether it ia of phyaiologic importance. 
In Part I, evidence waa preaented that SIP 24 ia a member of the 
cycloaporin A binding protein family. Cyclophilin, which ia a member of 
thia family, haa been implicated in playing an important role in 
regulating T lymphocyte activation and proliferation (190). If SIP 24 
ia able to bind cycloaporin A, then a cyclosporin A binding protein may 
be regulated by bFGF, through protein kinaae C. 
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GENERAL SUMMARY 
Th# raaulta of thla rasaarch hav# yielded much information about 
the auperinducible protein, SIP 24. The effects and mechanism of action 
of several agents on SIP 24 expression were studied. It was found that 
the phorbol ester, 12-0-tetradecanoylphorbol-13-acetate (TPA), increased 
expression of SIP 24. Addition of TPA with cycloheximide (CHX) resulted 
in a synergistic increase in SIP 24 levels. The fact that TPA is an 
activator of protein kinase C (pkC) lead to a further investigation of 
whether this second messenger pathway was responsible for the increased 
SIP 24 levels seen upon addition of bFGF. Studies with diacylglycerol 
revealed that this in vivo activator of protein kinase c increased SIP 
24 expression. Down regulation studies of protein kinase C further 
showed that the stimulatory effects of bFGF and TPA could be reduced 
upon pre-saturation with phorbol ester. Finally, studies with the pkC 
inhibitor, H-7, showed that the increased expression of SIP 24 mediated 
via TPA or bFGF could be reduced when H-7 was present. All the data 
taken together leads to the conclusion that the increased expression of 
SIP 24 seen in Balb/C 3T3 cells upon stimulation with bFGF is through 
protein kinase C. 
The combination of the glucocorticoid analog, dexamethasone, and 
cycloheximide also resulted in a synergistic expression of SIP 24. One 
of the pathways known to effect glucocoricoid action, the cyclic AHP-
dependent kinase pathway, was studied in detail. Studies with 
forskolin, cholera toxin, and dibutyryl cAMP revealed that SIP 24 
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•xpraaalon could b# incr#a**d upon addition of thaaa aganta to Balb/c 
3T3 calla. Thaaa aganta induea high intraeallular lavala of cAMP. Tha 
proataglandina, and Eg, alao raiaa cANP lavala, but do not induce SIP 
24. Thia laada to tha quaation of whathar or not thaaa aganta ara 
phyaiological ragulatora of SIP 24. 
SIP 24 waa purifiad and polyclonal antibodiaa wara obtainad, from 
which a radioimmunoaaaay (RIA) waa davalopad. Thia RIA waa uaad to 
acraan column fractiona in aubaequant SIP 24 purificationa. 
Charactarisation atudiaa ravaalad that SIP 24 ia a glycoprotein 
with 3-4,000 daltona of N-linkad carbohydrate. By comparing ita 
mobility on reducing veraua nonreducing SDS-polyacrylamide gel 
electrophoreaia, SIP 24 alao waa found to contain intramolecular 
diaulfide bonda. 
A partial amino acid sequence of SIP 24 waa determined from 
peptidea obtained after digaation with cloatripain. Two of the 
peptidea, -RALSIGBK6FGYKGSSFH- and -SDNFR-, were found to have a very 
high aequence identity with cyclophilin, a cyclosporin A binding 
protein. The other two peptidea do not have a high homology to bovine 
cyclophilin. Although a cytoplasmic protein, cyclophilin has three 
potential sites for N-linked glycoaylation. Based on these results, we 
propose that SIP 24 is related to cyclophilin, and may be a secreted 
form of a cycloaporin A binding protein. 
Heaa and Colombani have hypothesized that sensitivity of cells to 
cyclosporin A (CsA) may reside in the relative concentration of 
cyclophilin to calmodulin (213). Cyclosporin A binds to calmodulin and 
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inhibits the calmodulin-dapandant activation of protein kinasas (214). 
Other raaulta ahow that calmodulin and myoain light-chain kinaaa 
asaociata with tha nuclaar matrix and hava baan implicated in gana 
activation and tranacription (215). Mangar at al. hava found that tha 
dacraaaa in intarlaukin-2 and intarlaukin-3 mRNA by cycloaporin A ia 
dapandant on inhibiting tha mambrana-cytoplaamic aignal. So it appaara 
that cycloaporin A can inhibit tha calmodulin-dapandant transduction 
aignal, and tharaby pravant T lymphocyte activation and proliferation. 
If SIP 24 ia found to bind cycloaporin A, then aa Heaa and Colombani 
have hypotheaized, the cyclosporin A binding protein (SIP 24) could act 
as a sink and remove CsA from interacting with calmodulin and allow for 
maturation of T lymphocytes (213). In light of the evidence with 
regulation of SIP 24 expression and growth factors, it is tempting to 
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